How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Sell
28
IMDX Quote, Financials, Valuation and Earnings
Last price:
$2.84
Seasonality move
:
-2.21%
Day range:
$2.70 - $3.01
52-week range:
$1.92 - $4.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.60x
P/B ratio:
7.78x
Volume:
48.3K
Avg. volume:
116.3K
1-year change:
-17.26%
Market cap:
$79.5M
Revenue:
$1.9M
EPS (TTM):
-$3.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics
|
$292K | -$0.24 | 180.72% | -33.33% | -- |
|
APDN
Applied DNA Sciences
|
$1.3M | -$37.50 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte
|
$120.9M | $0.30 | 6.44% | 332.6% | $40.33 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics
|
$2.78 | -- | $79.5M | -- | $0.00 | 0% | 12.60x |
|
APDN
Applied DNA Sciences
|
$4.98 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
FONR
Fonar
|
$16.00 | -- | $100.7M | 12.80x | $0.00 | 0% | 0.99x |
|
PRPH
ProPhase Labs
|
$0.42 | $13.80 | $17.3M | -- | $0.00 | 0% | 2.26x |
|
VCYT
Veracyte
|
$25.24 | $40.33 | $2B | 61.56x | $0.00 | 0% | 4.31x |
|
XWEL
XWELL
|
$1.01 | -- | $5.3M | -- | $0.00 | 0% | 0.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics
|
-- | -1.933 | -- | 3.57x |
|
APDN
Applied DNA Sciences
|
-- | 5.076 | -- | 3.97x |
|
FONR
Fonar
|
-- | 1.699 | -- | 9.69x |
|
PRPH
ProPhase Labs
|
22.08% | -3.124 | 25.51% | 0.84x |
|
VCYT
Veracyte
|
-- | 2.266 | -- | 4.54x |
|
XWEL
XWELL
|
-- | 0.204 | -- | 1.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics
|
$1.3M | -$5.9M | -693.81% | -693.81% | -310.66% | -$6.2M |
|
APDN
Applied DNA Sciences
|
$370.9K | -$3.5M | -84.02% | -84.02% | -352.03% | -$3.4M |
|
FONR
Fonar
|
$12.1M | $3.7M | 5.32% | 5.33% | 15.23% | $2.5M |
|
PRPH
ProPhase Labs
|
$526K | -$3.7M | -101.67% | -144.22% | -289.24% | -$3.4M |
|
VCYT
Veracyte
|
$79.5M | $1.2M | 2.85% | 2.85% | 1.02% | $3.5M |
|
XWEL
XWELL
|
$1.3M | -$3.2M | -153.74% | -153.74% | -64.9% | -$4.6M |
Insight Molecular Diagnostics vs. Competitors
-
Which has Higher Returns IMDX or APDN?
Applied DNA Sciences has a net margin of -312.02% compared to Insight Molecular Diagnostics's net margin of -336%. Insight Molecular Diagnostics's return on equity of -693.81% beat Applied DNA Sciences's return on equity of -84.02%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics61.97% -$0.26 $10.2M APDNApplied DNA Sciences37.71% -$230.25 $10.2M -
What do Analysts Say About IMDX or APDN?
Insight Molecular Diagnostics has a consensus price target of --, signalling upside risk potential of 94.85%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 451707%. Given that Applied DNA Sciences has higher upside potential than Insight Molecular Diagnostics, analysts believe Applied DNA Sciences is more attractive than Insight Molecular Diagnostics.
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics0 0 0 APDNApplied DNA Sciences0 1 0 -
Is IMDX or APDN More Risky?
Insight Molecular Diagnostics has a beta of 0.953, which suggesting that the stock is 4.652% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.226%.
-
Which is a Better Dividend Stock IMDX or APDN?
Insight Molecular Diagnostics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or APDN?
Insight Molecular Diagnostics quarterly revenues are $2.1M, which are larger than Applied DNA Sciences quarterly revenues of $983.4K. Insight Molecular Diagnostics's net income of -$6.7M is lower than Applied DNA Sciences's net income of -$3.3M. Notably, Insight Molecular Diagnostics's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics is 12.60x versus 0.06x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics12.60x -- $2.1M -$6.7M APDNApplied DNA Sciences0.06x -- $983.4K -$3.3M
-
Which has Higher Returns IMDX or FONR?
Fonar has a net margin of -312.02% compared to Insight Molecular Diagnostics's net margin of 9.23%. Insight Molecular Diagnostics's return on equity of -693.81% beat Fonar's return on equity of 5.33%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics61.97% -$0.26 $10.2M FONRFonar44.52% $0.37 $160.3M -
What do Analysts Say About IMDX or FONR?
Insight Molecular Diagnostics has a consensus price target of --, signalling upside risk potential of 94.85%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Insight Molecular Diagnostics has higher upside potential than Fonar, analysts believe Insight Molecular Diagnostics is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics0 0 0 FONRFonar0 0 0 -
Is IMDX or FONR More Risky?
Insight Molecular Diagnostics has a beta of 0.953, which suggesting that the stock is 4.652% less volatile than S&P 500. In comparison Fonar has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.238%.
-
Which is a Better Dividend Stock IMDX or FONR?
Insight Molecular Diagnostics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or FONR?
Insight Molecular Diagnostics quarterly revenues are $2.1M, which are smaller than Fonar quarterly revenues of $27.2M. Insight Molecular Diagnostics's net income of -$6.7M is lower than Fonar's net income of $2.5M. Notably, Insight Molecular Diagnostics's price-to-earnings ratio is -- while Fonar's PE ratio is 12.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics is 12.60x versus 0.99x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics12.60x -- $2.1M -$6.7M FONRFonar0.99x 12.80x $27.2M $2.5M
-
Which has Higher Returns IMDX or PRPH?
ProPhase Labs has a net margin of -312.02% compared to Insight Molecular Diagnostics's net margin of -209.38%. Insight Molecular Diagnostics's return on equity of -693.81% beat ProPhase Labs's return on equity of -144.22%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics61.97% -$0.26 $10.2M PRPHProPhase Labs36.76% $0.11 $19.4M -
What do Analysts Say About IMDX or PRPH?
Insight Molecular Diagnostics has a consensus price target of --, signalling upside risk potential of 94.85%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3217.31%. Given that ProPhase Labs has higher upside potential than Insight Molecular Diagnostics, analysts believe ProPhase Labs is more attractive than Insight Molecular Diagnostics.
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics0 0 0 PRPHProPhase Labs0 0 0 -
Is IMDX or PRPH More Risky?
Insight Molecular Diagnostics has a beta of 0.953, which suggesting that the stock is 4.652% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.412, suggesting its less volatile than the S&P 500 by 141.195%.
-
Which is a Better Dividend Stock IMDX or PRPH?
Insight Molecular Diagnostics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or PRPH?
Insight Molecular Diagnostics quarterly revenues are $2.1M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Insight Molecular Diagnostics's net income of -$6.7M is lower than ProPhase Labs's net income of $4M. Notably, Insight Molecular Diagnostics's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics is 12.60x versus 2.26x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics12.60x -- $2.1M -$6.7M PRPHProPhase Labs2.26x -- $1.4M $4M
-
Which has Higher Returns IMDX or VCYT?
Veracyte has a net margin of -312.02% compared to Insight Molecular Diagnostics's net margin of 6.16%. Insight Molecular Diagnostics's return on equity of -693.81% beat Veracyte's return on equity of 2.85%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics61.97% -$0.26 $10.2M VCYTVeracyte69.46% $0.09 $1.2B -
What do Analysts Say About IMDX or VCYT?
Insight Molecular Diagnostics has a consensus price target of --, signalling upside risk potential of 94.85%. On the other hand Veracyte has an analysts' consensus of $40.33 which suggests that it could grow by 59.8%. Given that Insight Molecular Diagnostics has higher upside potential than Veracyte, analysts believe Insight Molecular Diagnostics is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics0 0 0 VCYTVeracyte7 1 1 -
Is IMDX or VCYT More Risky?
Insight Molecular Diagnostics has a beta of 0.953, which suggesting that the stock is 4.652% less volatile than S&P 500. In comparison Veracyte has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.062%.
-
Which is a Better Dividend Stock IMDX or VCYT?
Insight Molecular Diagnostics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or VCYT?
Insight Molecular Diagnostics quarterly revenues are $2.1M, which are smaller than Veracyte quarterly revenues of $114.5M. Insight Molecular Diagnostics's net income of -$6.7M is lower than Veracyte's net income of $7M. Notably, Insight Molecular Diagnostics's price-to-earnings ratio is -- while Veracyte's PE ratio is 61.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics is 12.60x versus 4.31x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics12.60x -- $2.1M -$6.7M VCYTVeracyte4.31x 61.56x $114.5M $7M
-
Which has Higher Returns IMDX or XWEL?
XWELL has a net margin of -312.02% compared to Insight Molecular Diagnostics's net margin of -67.19%. Insight Molecular Diagnostics's return on equity of -693.81% beat XWELL's return on equity of -153.74%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics61.97% -$0.26 $10.2M XWELXWELL18.78% -$1.00 $3.4M -
What do Analysts Say About IMDX or XWEL?
Insight Molecular Diagnostics has a consensus price target of --, signalling upside risk potential of 94.85%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 593.07%. Given that XWELL has higher upside potential than Insight Molecular Diagnostics, analysts believe XWELL is more attractive than Insight Molecular Diagnostics.
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics0 0 0 XWELXWELL0 0 0 -
Is IMDX or XWEL More Risky?
Insight Molecular Diagnostics has a beta of 0.953, which suggesting that the stock is 4.652% less volatile than S&P 500. In comparison XWELL has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.
-
Which is a Better Dividend Stock IMDX or XWEL?
Insight Molecular Diagnostics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or XWEL?
Insight Molecular Diagnostics quarterly revenues are $2.1M, which are smaller than XWELL quarterly revenues of $7M. Insight Molecular Diagnostics's net income of -$6.7M is lower than XWELL's net income of -$4.7M. Notably, Insight Molecular Diagnostics's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics is 12.60x versus 0.15x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics12.60x -- $2.1M -$6.7M XWELXWELL0.15x -- $7M -$4.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
78
SBET alert for Jul 16
SharpLink Gaming [SBET] is up 28.58% over the past day.
Buy
75
MP alert for Jul 16
MP Materials [MP] is up 0.48% over the past day.
Sell
38
NAIL alert for Jul 16
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 2.38% over the past day.
